Hold ABBV; collect 2.77% dividend, add at $240–242, trim toward $260
Hold ABBV. The 8/11 prior call is the binding precedent: when PEG is mechanically distorted by $5.8B in trailing special charges and the 15.3x forward multiple already reflects normalized earnings, fair value offers no margin of safety (the call returned -0.5%/-0.8% alpha). The Research Manager's PEG recalibration to 0.7–0.8 at realistic 10–12% growth rates is the correct framework. The aggressive analyst's "coiled spring" framing is not supported by MACD (line 0.98 below signal 2.49, histogram -1.51), and the asymmetric math is inverted (5–6% upside to $263 vs 10–11% downside to $222 is ~2:1 against, not in favor). The conservative analyst's FCF decline concerns (documented $6.64B → $3.11B multi-quarter trend) and structural constraints (negative book equity -$5.94B, 0.81 current ratio) are real but partially mitigated by Q2 WC drag being timing-related (AR build of $1.37B signals revenue growth). The existing position's $222 hard stop (200 SMA) protects against downside; fresh adds at $242 and $248 with a tightened ~$230 stop provide convexity. The setup is operationally sound (Skyrizi/Rinvoq >20% immunology growth, 47.8% EBITDA margin, 1.9x FCF/dividend coverage) but catalyst-light, warranting Hold until Q3 2026 earnings or technical reclamation at $252.58.
| Position | Action |
|---|---|
| Existing position | Maintain current allocation with $222 hard stop (200 SMA) |
| Price reaches $240–242 (50 SMA zone) | Scale in/add position for convexity |
| Price reaches $248 | Scale in/add position |
| Fresh add executed | Tighten stop to ~$230 (aligns with 2x ATR discipline) |
| Price above $255 | No adds above this level |
| Price reaches $252.58 | Partial trim trigger (Bollinger midline reclaim) for gradient exit |
| Price reaches $260–263 | Trim into resistance |
AbbVie's post-Humira transition has already succeeded, with Skyrizi/Rinvoq combined with Allergan Aesthetics delivering accelerating revenue and earnings that exceed Humira's peak, supported by best-in-class margins and fortress cash flow at a compelling Forward P/E of 15.28x and PEG of 0.41.
| Indicator | Value | Signal |
|---|---|---|
| close_50_sma | 242.13 | bullish |
| close_200_sma | 222.41 | bullish |
| close_10_ema | 249.06 | bearish |
| macd | 0.98 | bearish |
| macd_signal | 2.49 | bearish |
| macd_histogram | -1.51 | bearish |
| rsi | 50.78 | neutral |
| boll_mid | 252.58 | bearish |
| boll_upper | 264.65 | neutral |
| boll_lower | 240.51 | bullish |
| atr | 6.19 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price at $248
Then: Scale in for convexity
AbbVie has best-in-class margin profile among mega-cap pharma
↩ rebuts: “Bear concern about operational efficiency”
EV: +10-15% before dividend (target $263-270 vs current $248.76) · concedes: TTM P/E of 70.07 is genuinely elevated (though distorted by $2.7B in unusual charges in Q3 2025); Negative book value is real, though structural from Allergan goodwill/intangibles amortization and buybacks; Total debt of $70.82B is substantial; Q3 2025 trough EPS of $0.10 was a real earnings depression during Humira transition
AbbVie is a defensive income name with a stretched valuation, weakening cash generation, and a balance sheet that requires continuous credit market access to function, with risk/reward asymmetric to the downside.
· concedes: Q2 2026 operating income showed real 15.7% sequential increase from Q4 2025 ($6.72B vs $5.81B); Q2 2026 revenue grew +10.2% YoY (excellent for a mega-cap); Net leverage at 2.1x is manageable in absolute terms; AbbVie dividend has grown every year since spin-off; Stock has returned 8% YTD (positive absolute return)
→ vs conservative: Shorting this stock is strategically and mathematically wrong - beta of 0.28 means paying full borrow costs with limited downside velocity while paying dividend to borrow
→ vs conservative: The conservative case completely falls apart - holding a short against 1.9x dividend coverage and 23 billion FCF is asymmetric risk
→ vs neutral: Waiting for confirmation above 252.58 means buying 4 to 6 percent higher for the same setup available today
→ vs neutral: MACD cross below signal in a structurally bullish stock is a gift not a warning - bears exhausting themselves selling into 200 SMA support
→ vs conservative: 8 billion Apogee debt framing ignores net debt to EBITDA of 2.1x and 23 billion FCF - mischaracterizes balance sheet risk
→ vs neutral: Anyone framing MACD bearish cross as reason to trim is misreading the signal entirely - it's a coiled spring setup
| vwma | N/A (vendor data unavailable) | neutral |
Support: 245.52 · 242.13 · 240.51 · 222.41 | Resistance: 249.06 · 252.58 · 259.36 · 263.3
ABBV exhibits a classic bullish MA stack (Price > 50 SMA > 200 SMA, all rising) with the 50 SMA at $242.13 (+2.7%) and 200 SMA at $222.41 (+11.8%), confirming the medium- and long-term uptrends are intact. Momentum is the weakest leg: MACD has bearish-crossed (MACD 0.98 below signal 2.49, histogram -1.51), RSI has reset to neutral at 50.78 after reaching overbought (77.2 on 2026-07-02), and price trades just below the 10 EMA at 249.06. Bollinger Bands show price between the lower band (240.51) and midline (252.58), with ATR elevated at 6.19. The recommendation is HOLD: maintain exposure while the uptrend holds above 242.13, avoid adding fresh longs until price reclaims 252.58+ on rising volume, and consider trimming into rallies toward 252–260 while reloading on weakness toward the 50 SMA.
Market Cap
$439.59 B
P/E (TTM)
70.07
Forward P/E
15.28
PEG Ratio
0.41
P/B
-74.06
EV/EBITDA
~16.3x
52-Week High
$267.47
52-Week Low
$190.75
50-DMA
$242.39
200-DMA
$225.28
Beta
0.28
Dividend Yield
2.77%
Revenue (TTM)
$64.39 B
Gross Margin
72.8%
EBITDA
$30.76 B
EBITDA Margin
47.8%
Operating Margin
40.0%
Net Margin
9.8%
ROA
10.5%
EPS (TTM)
$3.55
Forward EPS
$16.28
Total Assets
$135.1 B
Cash & Equivalents
$6.57 B
Total Debt
$70.82 B
Net Debt
$64.25 B
Net Debt / EBITDA
2.1x
Stockholders' Equity
-$5.94 B
Goodwill + Intangibles
$84.66 B
Current Ratio
0.81
Operating CF (TTM)
~$24.6 B
Free Cash Flow (TTM)
~$23.1 B
FCF per Share
~$13.0
Dividend Coverage
1.9x
Annual Amortization (Intangibles)
~$7 B/year
Strengths
Concerns
AbbVie is a best-in-class large-cap pharmaceutical company with industry-leading margins (40% operating, 47.8% EBITDA) and robust FCF generation of ~$23.1B TTM, though GAAP earnings are significantly distorted by ~$7B annual intangible amortization and periodic impairment charges. The forward P/E of 15.28x and PEG of 0.41 indicate the stock is fairly valued to modestly undervalued on normalized earnings (Forward EPS $16.28 vs. TTM EPS $3.55). The Q2 2026 earnings print validates the earnings normalization thesis with EPS of $2.03 and net income of $3.61B. While the $70.82B debt load and structural negative book equity warrant monitoring, the 2.1x Net Debt/EBITDA leverage and 1.9x dividend coverage confirm financial robustness. AbbVie's defensive characteristics (Beta 0.28, 2.77% yield) and post-Humira franchise strength (Skyrizi/Rinvoq) make it suitable for both GARP and dividend growth strategies.
Macro: Soft CPI print in early August 2026 triggered a Nasdaq rally while the broader tape stayed mixed; headline disinflation trend supports multiple expansion for duration-sensitive equities. Fed is priced to hold with 86% probability of no cuts in 2026 (~$7.2M Polymarket volume, -2.5pp change last week), with 0% probability assigned to either 12+ cuts or 6 cuts — the dovish tail fully priced out. Recession odds remain low at 8% (-1.0pp/week), supporting the soft-landing base case. Higher-for-longer rates are mildly negative for high-yielding equities' relative appeal vs. bonds, but ABBV's ~3.2% dividend yield still screens favorably against an elevated 10-year yield.